CN115003385A - 双互补位cd73抗体 - Google Patents

双互补位cd73抗体 Download PDF

Info

Publication number
CN115003385A
CN115003385A CN202080092714.3A CN202080092714A CN115003385A CN 115003385 A CN115003385 A CN 115003385A CN 202080092714 A CN202080092714 A CN 202080092714A CN 115003385 A CN115003385 A CN 115003385A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antigen binding
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092714.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·洛德
K·拉多塞维奇
J·E·斯蒂法诺
Y·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN115003385A publication Critical patent/CN115003385A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080092714.3A 2019-11-15 2020-11-13 双互补位cd73抗体 Pending CN115003385A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962936119P 2019-11-15 2019-11-15
US62/936,119 2019-11-15
US202063023542P 2020-05-12 2020-05-12
US63/023,542 2020-05-12
US202063086982P 2020-10-02 2020-10-02
US63/086,982 2020-10-02
PCT/US2020/060434 WO2021097223A2 (en) 2019-11-15 2020-11-13 Biparatopic cd73 antibodies

Publications (1)

Publication Number Publication Date
CN115003385A true CN115003385A (zh) 2022-09-02

Family

ID=73790235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092714.3A Pending CN115003385A (zh) 2019-11-15 2020-11-13 双互补位cd73抗体

Country Status (13)

Country Link
US (1) US20220403041A1 (https=)
EP (1) EP4058150A2 (https=)
JP (2) JP7789667B2 (https=)
KR (1) KR20220100929A (https=)
CN (1) CN115003385A (https=)
AU (1) AU2020384305A1 (https=)
BR (1) BR112022009317A2 (https=)
CA (1) CA3161717A1 (https=)
CO (1) CO2022008204A2 (https=)
IL (1) IL292959A (https=)
MX (1) MX2022005866A (https=)
PH (1) PH12022551150A1 (https=)
WO (1) WO2021097223A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
JP2025521231A (ja) * 2022-06-08 2025-07-08 シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド Ｃｄ７３抗体カクテル療法
CN115991772B (zh) * 2022-08-12 2023-09-01 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766210A (zh) * 1999-08-24 2012-11-07 梅达里克斯公司 人ctla-4抗体及其应用
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
US20190031766A1 (en) * 2017-06-22 2019-01-31 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6385357B2 (ja) 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
GB2537445A (en) * 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
EP3423494A1 (en) * 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
CA3045376C (en) * 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE
US11530273B2 (en) * 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
EP3642240A1 (en) * 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
EP3762030A4 (en) * 2018-03-09 2022-01-05 Phanes Therapeutics, Inc. ANTI-CD73 ANTIBODIES AND USES THEREOF
TWI869346B (zh) * 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102766210A (zh) * 1999-08-24 2012-11-07 梅达里克斯公司 人ctla-4抗体及其应用
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
US20190031766A1 (en) * 2017-06-22 2019-01-31 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES E STEFANO ET AL.: "A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms", 《J BIOL CHEM》, vol. 295, no. 52, 29 October 2020 (2020-10-29), pages 18379 - 18389 *

Also Published As

Publication number Publication date
JP2026026484A (ja) 2026-02-17
US20220403041A1 (en) 2022-12-22
PH12022551150A1 (en) 2023-10-09
MX2022005866A (es) 2022-08-15
WO2021097223A2 (en) 2021-05-20
JP2023503846A (ja) 2023-02-01
KR20220100929A (ko) 2022-07-18
EP4058150A2 (en) 2022-09-21
IL292959A (en) 2022-07-01
CA3161717A1 (en) 2021-05-20
JP7789667B2 (ja) 2025-12-22
AU2020384305A1 (en) 2022-06-30
CO2022008204A2 (es) 2022-06-21
BR112022009317A2 (pt) 2022-08-09
WO2021097223A3 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7789667B2 (ja) 二重パラトープ性ｃｄ７３抗体
US20250011473A1 (en) ANTI-IgE ANTIBODIES
JP7757247B2 (ja) ヒト化またはキメラｃｄ３抗体
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
EP3172233B1 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
AU2018274919A1 (en) Bispecific heterodimeric diabodies and uses thereof
JP2015501814A (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
WO2015032906A2 (en) Cd70-binding peptides and method, process and use relating thereto
JP7419238B2 (ja) Ｐｄ１結合剤
CN120795158A (zh) 抗体
EP4155318A1 (en) Bispecific antibody and use thereof
WO2014028748A1 (en) Interleukin 2 antibodies and antibody complexes
JP2026508244A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
EP3317299A1 (en) Multi-specific binding proteins
CN117396182A (zh) 抗cea和抗cd137多特异性抗体及其使用方法
JP2022538374A (ja) Ｐｄｇｆ－ｂおよびｐｄｇｆ－ｄに結合する抗原結合分子ならびにその使用
RU2844809C1 (ru) Бипаратопные антитела к cd73
US20230151110A1 (en) Anti-cd47 antibody and uses thereof
TW202546003A (zh) 靶向人類白血球抗原g的抗體或其抗原結合片段及其應用
TW202545565A (zh) 高親和力b7h7抗體或其抗原結合片段及其用途
TW202613175A (zh) Cdh3結合蛋白及其用途
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体
HK40070445B (en) Anti-b7h4 antibody, and bispecific antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination